Analytical Method Development and Validation of Piracetam by UV Spectroscopic Method for Bulk and Pharmaceutical Dosage Form

Piracetam is a synthetic drug belonging to the racetam group of nootropic agents. It is chemically related to the neurotransmitter-modulating racetam class and has been studied for various neurological and cognitive disorders. The clinical use and approved indications of piracetam vary between countries. In the United Kingdom, for example, piracetam is licensed for the treatment of cortical myoclonus, in combination with other anti-myoclonic therapies. It is sometimes described as a “memory-enhancing” drug, but evidence supporting its routine use for improving memory in healthy people or treating dementia is limited and inconsistent.^[1]

Piracetam belongs to the nootropic/racetam class of drugs. Its ATC classification is N06BX03. Unlike conventional stimulants, piracetam does not act primarily by producing generalized central nervous system stimulation. Its pharmacological actions are complex, and its precise mechanism responsible for therapeutic effects in cortical myoclonus has not been completely established. Cognitive and neurological disorders comprise a broad group of conditions that affect functions such as memory, learning, attention, coordination, behaviour, and other aspects of central nervous system function.^[2] These disorders may arise from ageing, neurodegenerative processes, vascular abnormalities, metabolic disturbances, hypoxia, or structural and functional abnormalities of the brain. Because impairment of neuronal function can involve several interconnected mechanisms, various pharmacological agents have been investigated to improve or preserve neurological and cognitive function. Among these agents, nootropic drugs represent a group of compounds developed or investigated for their potential effects on cognitive and neuronal function. Piracetam is one of the best-known and earliest members of this group.^[3]

Piracetam is a synthetic compound chemically known as 2-oxo-1-pyrrolidine acetamide and is structurally related to the cyclic derivatives of gamma-aminobutyric acid (GABA). It is regarded as the prototype of the racetam family of nootropic compounds, which subsequently led to the development and investigation of structurally related compounds. Although piracetam has been studied for several neurological and cognitive conditions, its precise mechanism of action remains incompletely understood. The current UK product information classifies piracetam pharmacologically as a nootropic (ATC N06BX03) and specifically indicates its use for cortical myoclonus, where it is administered as an adjunct to other anti-myoclonic therapy.^[4]

Piracetam has attracted considerable scientific interest because of its reported effects on neuronal membrane properties, neurotransmission, neuroplasticity, and hemorheological functions. Experimental and pharmacological studies suggest that piracetam can influence membrane fluidity and modulate neurotransmission involving several systems, particularly cholinergic and glutamatergic pathways. However, it is important to note that no single mechanism has been universally accepted as responsible for all of its clinical effects. Reviews of the pharmacology of piracetam have emphasized that its mechanism remains complex and incompletely defined. In addition to its effects on the nervous system, piracetam demonstrates several hemorheological effects. According to the current product information, piracetam increases erythrocyte deformability and decreases platelet aggregation and erythrocyte adhesion to vascular endothelium. It has also been reported to influence blood viscosity and certain coagulation-related parameters. These properties have contributed to investigations of piracetam in various neurological and circulatory disorders. However, these pharmacological effects should not be interpreted as establishing piracetam as an approved treatment for every condition in which such effects have been studied.^[5]

Historically, piracetam has been investigated in conditions including cognitive impairment, dementia, vertigo, dyslexia, cortical myoclonus, and other neurological disorders. Nevertheless, the strength of evidence varies substantially between indications, and regulatory approval differs between countries. In particular, evidence supporting piracetam as a general cognitive or memory-enhancing drug is not conclusive. A recent systematic review and meta-analysis of piracetam in adults with memory impairment found no statistically significant overall improvement in memory compared with placebo, highlighting the need for caution when describing piracetam as a general memory-enhancing medicine.^[6]

Piracetam is also characterized by a distinctive pharmacokinetic profile. It is rapidly and almost completely absorbed following oral administration, with oral bioavailability close to 100%. It crosses the blood-brain barrier and is distributed to the central nervous system. Piracetam undergoes minimal metabolism and is eliminated predominantly through the kidneys, with approximately 90% of the administered dose excreted in the urine as unchanged drug. Consequently, renal function is an important consideration in patients receiving piracetam, particularly elderly patients and those with renal impairment. Overall, piracetam remains an important compound in the history and study of nootropic pharmacology. Its unique pharmacological properties, effects on neuronal membranes and hemorheology, and long history of investigation have made it a subject of considerable clinical and experimental research. However, its therapeutic role should be considered according to the specific indication, available clinical evidence, and regulatory status in the relevant country, rather than assuming that it is universally effective for cognitive enhancement or neurological disease.^[7]

Piracetam Structure:

Figure 1: Structure of Piracetam

Piracetam is a nootropic/racetam drug with the IUPAC name 2-(2-oxopyrrolidin-1-yl) acetamide, molecular formula C₆H₁₀N₂O₂, and molecular weight 142.16 g/mol. It is a white to almost white crystalline powder with a melting point of approximately 151–154 °C and is very soluble in water. Piracetam is essentially non-ionizable at physiological pH. It was developed by Corneliu E. Giurgea and colleagues at UCB Pharma, Belgium, and was introduced commercially in Europe under the brand name Nootropil.^[8,9] Its precise mechanism of action is not fully established, but it is thought to influence neuronal membrane properties and neurotransmission, including cholinergic and glutamatergic pathways. Following oral administration, piracetam is rapidly and almost completely absorbed, with bioavailability approaching 100%. It undergoes minimal hepatic metabolism and is eliminated predominantly unchanged through the kidneys, with an elimination half-life of approximately 5 hours in healthy adults; therefore, dose adjustment may be required in renal impairment. Piracetam is administered orally and, in some countries, by parenteral routes.^[10] Its approved therapeutic indications vary between countries; in the UK, it is licensed as an adjunctive treatment for cortical myoclonus. Reported adverse effects include nervousness, agitation, irritability, anxiety, headache, dizziness, sleep disturbances, and gastrointestinal symptoms. Caution is particularly required in patients with renal impairment or increased risk of bleeding. In India, the exact first approval date of piracetam as a standalone drug is not clearly established in currently accessible CDSCO records; however, CDSCO records document approval of piracetam-containing fixed-dose combinations, including citicoline sodium 500 mg + piracetam 800 mg, approved on 17 July 2015. ^[11,12]

UV SPECTROSCOPIC METHODOLOGY

Collection of reagents and solvents:

Piracetam API was received as a gift sample from Linux Life Sciences Pvt. Ltd., Puducherry, India and it was used as the reference standard for the analytical study. Piracetam tablets marketed under the brand name Cognitam-400, containing 400 mg of piracetam per tablet, were procured from a local pharmacy and used as the pharmaceutical dosage-form sample for UV spectrophotometric analysis. Distilled water was used as the solvent and diluent throughout the experimental procedure. Standard laboratory glassware, including volumetric flasks, pipettes, beakers, and measuring cylinders, was used for sample preparation and dilution. The piracetam tablets were accurately weighed, finely powdered, and an appropriate quantity of the powdered sample was transferred into a volumetric flask. The required volume was made up with distilled water to obtain the desired concentration for UV spectrophotometric analysis. The prepared solutions were analysed using a calibrated UV–Visible spectrophotometer with matched quartz cells.

Apparatus and Software:

An analytical weighing balance (Shimadzu AUX-220) was used for accurate weighing of the drug and tablet samples. An ultrasonic sonicator (Equitron, 230 V AC, 50 Hz) was employed for proper dissolution and extraction of the samples. A vacuum pump (Super Fit) and filtration kit (Tarsons) were used for sample filtration. 0.45 µm nylon membrane filters (Merck Millipore) were used for the filtration of solvents and sample solutions. The wavelength detection and UV spectrophotometric analysis were carried out using a double-beam UV–Visible spectrophotometer (Shimadzu UV-1800).

Preparation of Standard and Working Solutions of Piracetam:

The standard stock solution of piracetam (Stock-I) was prepared by accurately weighing 25 mg of piracetam and transferring it into a 25 mL volumetric flask. The drug was dissolved in distilled water, and the volume was made up to the mark with the same solvent to obtain a final concentration of 1000 µg/ml. The prepared stock solution was then sonicated for 5 minutes using a sonicator to ensure complete dissolution and uniformity. A secondary stock solution (Stock-II) having a concentration of 100 µg/ml was prepared by accurately transferring 10 mL of Stock-I into a 100 mL volumetric flask. The solution was diluted up to the mark with distilled water and mixed thoroughly.

From Stock-II, six working standard solutions of piracetam having concentrations of 10, 20, 30, 40, 50, and 60 µg/mL were prepared by appropriate dilution with distilled water. The required volume of Stock-II was transferred into individual volumetric flasks and diluted up to the respective final volume with distilled water. The prepared working standard solutions were then sonicated for 5 minutes to ensure homogeneity. The absorbance of each working standard solution was subsequently measured using a UV–Visible spectrophotometer at the predetermined wavelength of maximum absorption (λ max) of piracetam, using distilled water as the blank. The absorbance values obtained for the different concentrations were used to construct the calibration curve of piracetam by plotting absorbance against concentration.

Figure 2: UV Absorption maxima of piracetam

Figure 3: Linearity graph of Piracetam

4. Limit of detection (LOD) and Limit of quantification (LOQ)

LOD and LOQ were calculated according to ICH recommendations where the approach is based on the signal-to-noise ratio. Chromatogram signals obtained with known low concentrations of analytes were compared with the signals of blank samples. A signal-to-noise ratio of 3:1 and 10:1 was considered for calculating LOD and LOQ respectively.

Table 4: LOD and LOQ for Piracetam

5. Robustness

The robustness of an analytical procedure describes its capability to remain unaffected by small and deliberate variation in the chromatographic conditions and is found to be unaffected by small variation ±0.1ml/min in wavelength results are shown in the table.

Table 5: Robustness for Piracetam

The absorbance values show only a small variation when the wavelength was deliberately changed by ±1 nm from the selected wavelength of 209 nm. The mean absorbance is approximately 0.783, indicating that the change in wavelength had no significant effect on the analytical response. Therefore, the proposed UV–Visible spectrophotometric method can be considered robust with respect to wavelength variation.

The analytical method for Piracetam was optimized to establish suitable experimental conditions that provide accurate, precise, sensitive, and reproducible results. Different analytical parameters such as wavelength, solvent/diluent, concentration range, and robustness were evaluated during method development. Based on the optimization studies, distilled water was selected as the suitable diluent and 209 nm was selected as the optimum detection wavelength for Piracetam. The optimized method showed good linearity over the range of 10–60 µg/mL with an R² value of 0.9993. The method also demonstrated satisfactory precision, accuracy, sensitivity, and robustness, confirming the suitability of the optimized conditions for quantitative estimation of Piracetam by UV–Visible spectrophotometry.

Table 6: Optimum Conditions of UV Spectroscopic Method of Piracetam

DISCUSSION:

The developed UV–Visible spectrophotometric method for the estimation of Piracetam was evaluated for linearity, precision, accuracy, robustness, and sensitivity. The method showed good linearity over the concentration range of 10–60 µg/mL at 209 nm, with a correlation coefficient (R²) of 0.9957, indicating an excellent linear relationship between concentration and absorbance. The precision study showed low %RSD values ranging from 0.885–1.204% for intra-day and inter-day measurements, demonstrating good repeatability and reproducibility of the method. The accuracy study showed percentage recoveries of 99.85%, 100.08%, and 99.98% at 80%, 100%, and 120% levels, respectively. These results indicate that the method is accurate for the estimation of Piracetam. The robustness study performed at 208, 209, and 210 nm showed only minor variations in absorbance (0.779–0.780), indicating that the method was not significantly affected by small changes in wavelength. The reported LOD and LOQ were 4.53 µg/mL and 13.73 µg/mL, respectively, indicating adequate sensitivity for quantitative analysis within the validated range. Overall, the developed UV–Visible spectrophotometric method was found to be simple, accurate, precise, linear, sensitive, and robust, and can be used for the routine estimation of Piracetam in pharmaceutical dosage forms.

CONCLUSION:

In conclusion, Piracetam is an important nootropic drug that requires reliable and reproducible analytical methods for its quantitative estimation in pharmaceutical formulations. UV–Visible spectrophotometry provides a simple, rapid, economical, and easily accessible analytical technique for the determination of Piracetam based on its absorption characteristics. In the present study, the developed method demonstrated satisfactory analytical performance with good linearity, precision, accuracy, sensitivity, and robustness. The method showed a linear response over the selected concentration range and provided consistent absorbance measurements with good recovery of the drug. The low variation observed during precision and robustness studies further indicated the reliability and reproducibility of the method. Therefore, the developed UV–Visible spectrophotometric method can be considered a suitable and practical approach for the routine quantitative estimation and quality control of Piracetam in pharmaceutical dosage forms..

REFERENCES

1. UCB Pharma Ltd. Nootropil 1200 mg film-coated tablets: Summary of Product Characteristics [Internet]. Electronic Medicines Compendium; 2025
2. Winblad B. Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev. 2005;11(2):169-182.
3. Malykh AG, Sadaie MR. Piracetam and piracetam-like
4. drugs: from basic science to novel clinical applications to CNS disorders. Drugs. 2010;70(3):287-312.
5. Gouhie FA, Barbosa KO, Cruz ABR, Wellichan MM, Zampolli TM. Cognitive effects of piracetam in adults with memory impairment: a systematic review and meta-analysis. Clin Neurol Neurosurg. 2024;243:108358.
6. Tacconi MT, Wurtman RJ. Piracetam: physiological disposition and mechanism of action. Adv Neurol. 1986;43:675-685.
7. Nickolson VJ, Wolthuis OL. Piracetam: novel pharmacological properties and therapeutic applications. Pharmacol Ther. 1988;37(3):365-378.
8. Winblad B. Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev. 2005;11(2):169-182.
9. Gouliaev AH, Senning A. Piracetam and other structurally related nootropics. Brain Res Brain Res Rev. 1994;19(2):180-222.
10. Nootropil 1200 mg film-coated tablets – Summary of Product Characteristics. Electronic Medicines Compendium (emc). Piracetam pharmacology, therapeutic indication, pharmacokinetics and elimination.
11. European Medicines Agency (EMA). Piracetam: List of nationally authorised medicinal products.
12. Central Drugs Standard Control Organisation (CDSCO), Government of India. Approved New Drugs/FDC approval records.
13. International Conference on Harmonisation (ICH). Q2(R1): Validation of Analytical Procedures: Text and Methodology. ICH Harmonised Tripartite Guideline, Current Step 4 version, November 2005.